Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

 Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

Shots:

  • The companies entered into an agreement to assess insulin dose data from Novo Nordisk’ pre-filled insulin pen connected to the digital health tool marked with Abbott’s FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system)
  • The focus of an agreement is to advance management techniques for diabetes with the combination of the two technologies CGM & connected insulin pen, enabling healthcare professionals to monitor glucose and insulin data
  • In H1’17, Novo signed a collaboration with Glooko for its platform connected to insulin pens for uploading data by any means of communication-capable Android phone. Abbott’s FreeStyle Libre system uses sensors allowing the monitor glucose levels in real-time with an eight-hour glucose history & change in glucose level

Click here to read full press release/ article | Ref: Abbott | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post